European watchdogs recall copycat Plavix; Pfizer loses Lipitor patent fight in S. Korea;

    @FiercePharma: Are me-too drugs doomed to suffer? Article | Follow @FiercePharma

> The European Medicines Agency has recommended the recall of all batches of generic Plavix from Swiss drugmaker Acino made at a factory in India because of quality concerns about the drug. Report

> Pfizer lost patent suits in South Korea related to the cholesterol pill Lipitor, ending an almost two-year legal battle. Report

> Shire is reporting data the company says proves it is safe to switch to the company's newly approved drug to treat Gaucher's disease, from a better-known rival produced by Genzyme. Report

> Sinopharm Group posted a forecast-lagging 43 percent rise in second-half earnings, as China's largest drug distributor expanded its sales network and broadened its production range to tap the country's estimated $44 billion healthcare market. Report

> Jazz Pharmaceuticals received notice from Lonza that the manufacturer intends to terminate its agreement to supply the drugmaker with sodium gamma hydroxybutyrate. Report

> GlaxoSmithKline exercised its option to buy 1.56 million common shares of JCR Pharmaceuticals. Report

Biotech News

  @FierceBiotech: Genentech looking to hire smart, creative types. Report | Follow @FierceBiotech

   @JohnCFierce: Glad to see reform story can fade now. For a daily grunt like me, it seems to be sucking all the air out of the biotech newsroom. | Follow @JohnCFierce

> CorMedix files IPO. Story

> Resignation sparks buyout rumors at BioMarin. Item

> Adaptive TCR grabs $4.5 million in funding. Report

> FDA panel to review Vivus drug in July. Article

> The WHO projects about 2.3 billion adults will be overweight and more than 700 million will be obese by 2015. And with few obesity drug options on the market, venture capitalists are eager to invest in companies developing therapies for this difficult-to-treat condition. Item

And Finally... Scientists have found a new and simple way to identify breast cancer patients who are likely to respond well to treatment with a common class of chemotherapy drugs. Report